Tracheoesophageal fistula development following radiotherapy and tyrosine kinase inhibitors in a patient with advanced follicular thyroid carcinoma: a case-based review.
Carcinoma
Case report
Follicular thyroid complications
Radiation therapy
Tracheoesophageal fistula
Tyrosine kinase inhibitor
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
received:
18
09
2023
accepted:
23
10
2023
medline:
3
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
aheadofprint
Résumé
Tracheoesophageal fistulas (TEF) are a rare complication that can occur in patients with radioactive iodine refractory metastatic follicular thyroid carcinoma (FTC) following treatment with radiotherapy (RT) and tyrosine kinase inhibitors (TKI). We describe the case of a TEF development in a 69-year-old male who underwent targeted therapy TKIs and adjuvant RT for radioactive iodine refractory FTC. In the case, staging investigations revealed a metastatic, poorly differentiated FTC refractory to radioactive iodine. After 2 years of disease control on Lenvatinib, the patient's condition progressed, necessitating a switch to Cabozantinib. Soon after, they presented with haemoptysis secondary to invasion of the primary thyroid tumour into the trachea. Radical radiotherapy (45 Gy/30 fractions) was also administered to the thyroid gland, ultimately complicated by radiation necrosis. Four months post-completion of RT and recommencing TKI, the patient presented with haemoptysis and hoarseness secondary to recurrent laryngeal nerve compression and tracheal invasion, as well as dysphagia secondary to oesophageal compression. Following an acute presentation with intractable throat pain, investigations revealed a TEF. Surgical and endoscopic management was deemed inappropriate given the patient's rapid deterioration and anatomical position of the TEF, and therefore a palliative approach was taken. This case report highlights a rare cause of TEF development in a patient having TKI therapy post-RT for advanced FTC. It highlights the importance of monitoring TEF development in this cohort of patients. It demonstrates the importance of patient counselling and education regarding treatment options and the rare side effects of treatments.
Identifiants
pubmed: 37922099
doi: 10.1007/s11845-023-03559-4
pii: 10.1007/s11845-023-03559-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.
Références
Mazeh H, Orlev A, Mizrahi I, Gross DJ, Freund HR. Concurrent medullary, papillary, and follicular thyroid carcinomas and simultaneous Cushing’s syndrome. Eur Thyroid J. 2015 Mar;4(1):65–8. https://doi.org/10.1159/000368750 . Epub 2014 Nov 22. PMID: 25960965; PMCID: PMC4404927.
Lo CY, Chan WF, Lam KY, Wan KY (2005) Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg 242(5):708–715. https://doi.org/10.1097/01.sla.0000186421.30982.d2 . PMID: 16244545; PMCID: PMC1409851.
Badulescu CI, Piciu D, Apostu D, Badan M, Piciu A. Follicular thyroid carcinoma-clinical and diagnostic findings in a 20-year follow up study. Acta Endocrinol (Buchar). 2020 Apr-Jun;16(2):170–177. https://doi.org/10.4183/aeb.2020.170 . PMID: 33029233; PMCID: PMC7535902.
Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov;8(11):1277–86; quiz 1287. https://doi.org/10.6004/jnccn.2010.0094 . PMID: 21081784.
Song, E. et al. (2016) ‘Development of tracheoesophageal fistula after the use of sorafenib in locally advanced papillary thyroid carcinoma: a case report’, International Journal of Thyroidology, 9(2), p. 210. https://doi.org/10.11106/ijt.2016.9.2.210 .
Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014 May;24(5):918–22. https://doi.org/10.1089/thy.2012.0598 . Epub 2014 Mar 17. PMID: 24635127; PMCID: PMC4026371.
Iwasaki H, Toda S, Murayama D, Kato S, Matsui A. Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis. Mol Clin Oncol. 2021 Feb;14(2):28. https://doi.org/10.3892/mco.2020.2190 . Epub 2020 Dec 16. PMID: 33414909; PMCID: PMC7783723.
Valerio L, Giani C, Agate L, Molinaro E, Viola D, Bottici V, Matrone A, Puleo L, Lorusso L, Cappagli V, Ribechini A, Elisei R. Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer. Eur Thyroid J. 2021 Jul;10(5):399–407. https://doi.org/10.1159/000514182 . Epub 2021 Mar 23. PMID: 34540710; PMCID: PMC8406256.
Shah DR, Dholakia S, Shah RR (2014) Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients. Drug Saf 37(3):135–149. https://doi.org/10.1007/s40264-014-0139-x . PMID: 24526268
Hu Y, Zhao YF, Chen LQ, Zhu ZJ, Liu LX, Wang Y et al (2009) Comparative study of different treatments for malignant tracheoesophageal/bronchoesophageal fistulae. Dis Esophagus 22(6):526–531
doi: 10.1111/j.1442-2050.2009.00950.x
pubmed: 19302211
Niu G, Chen X (2010) Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 11(8):1000–1017. https://doi.org/10.2174/138945010791591395 . PMID: 20426765; PMCID: PMC3617502.
Salik I, Paul M. Tracheoesophageal fistula. [Updated 2023 Jan 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535376/
. 13.Zhou C, Hu Y, Xiao Y, Yin W. Current treatment of tracheoesophageal fistula. Ther Adv Respir Dis. 2017 Apr;11(4):173–180. https://doi.org/10.1177/1753465816687518 . Epub 2017 Feb 13. PMID: 28391759; PMCID: PMC5933624.
Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N et al (2010) Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28(1):43–48
doi: 10.1200/JCO.2009.24.7353
pubmed: 19901100
Gore E, Currey A, Choong N (2009) Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. J Thorac Oncol 4(12):1590–1591
doi: 10.1097/JTO.0b013e3181c06a6f
pubmed: 20009916
Abugroun A, Ahmed F, Singh N, Nadiri M. Late onset chemo/radiation induced tracheoesophageal fistula in squamous cell cancer of the lung. World J Oncol. 2017 Oct;8(5):171–173. https://doi.org/10.14740/wjon1063w . Epub 2017 Nov 5. PMID: 29147454; PMCID: PMC5687897.
Gschossmann JM, Bonner JA, Foote RL, Shaw EG, Martenson JA Jr, Su J (1993) Malignant tracheoesophageal fistula in patients with esophageal cancer. Cancer 72:1513–1521
doi: 10.1002/1097-0142(19930901)72:5<1513::AID-CNCR2820720504>3.0.CO;2-G
pubmed: 7688653
Hindy P, Hong J, Lam-Tsai Y, Gress F. A comprehensive review of esophageal stents. Gastroenterol Hepatol (N Y). 2012 Aug;8(8):526–34. PMID: 23293566; PMCID: PMC3533211.
Martinez JC, Puc MM, Quiros RM. Esophageal stenting in the setting of malignancy. ISRN Gastroenterol. 2011;2011:719575. https://doi.org/10.5402/2011/719575 . Epub 2011 Aug 8. PMID: 21991527; PMCID: PMC3168502.